tPA for CVA: Reconciling the ACEP, FDA, and ASA Guidelines - Dr. Asimos

1. The controversy regarding IV tPA treatment for stroke cannot be resolved with the current evidence
2. Recent FDA labeling changes and potential conflicts between the ACEP and the AHA/ASA policy recommendations have only fueled the tPA controversy 
3. Advanced imaging practices will likely lead to improvement in determining which patients are likely to benefit or be harmed from IV tPA treatment
4. You are much more likely to be sued for not treating a perceived IV tPA eligible patient than for treating someone who sustains an ICH after tPA treatment

---